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Abstract 
It is a major challenge to guarantee homogeneous acquisition during a prospective multicentre 
MRI study which makes use of different devices. The goal of the multicentre Grand Ouest 
Glioblastoma Project was to correlate MRI quantitative parameters with biological markers 
extracted from image-guided biopsies. Therefore, it was essential to ensure spatial coherence 
of the parameters as well as the signal intensity and homogeneity. The project included the 
same MRI protocol implemented on six devices from different manufacturers. The key point 
was the initial acceptance of the imaging devices and protocol sequences. For this purpose, 
and to allow comparison of quantitative patient data, we propose a specific method for quality 
assessment. A common quality control based on 10 parameters was established. Three pulse 
sequences of the clinical project protocol were applied using three test-objects. A fourth test-
object was used to assess T1 accuracy. Although geometry-related parameters, Signal-to-
Noise Ratio, uniformity and T1 measurements varied slightly depending on the different 
devices, they nevertheless remained within the recommendations and expectations of the 
multicentre project. This kind of quality control procedure should be undertaken as a 
prerequisite to any multicentre clinical project involving quantitative MRI and comparison of 
data acquisitions with quantitative biological image-guided biopsies.  
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Introduction 
Quality-assessment (QA) protocols are now routinely applied to clinical Magnetic Resonance 
Imaging (MRI) devices. There are usually two main issues involved in QA: checking 
installation of the new device and longitudinal follow up of MRI system performances. In 
most cases, these QA procedures are manufacturer-specific, so they cannot be used for 
multicentre projects involving multiple MRI systems from different manufacturers and 
operated on different sites. To harmonize test methods, several groups (AAPM, NEMA and 
COMAC-BME) [1-9] have proposed QA protocols for MRI. The purpose of these 
longitudinal QA protocols is to monitor the performances of the MRI device [10-14]. Stable 
technical parameter values lying within the tolerance limits ensure that high-quality 
reproducible images can be obtained.  
The goal of the multicentre Grand Ouest Glioblastoma Project (GOGP) [15] was to 
correlate MRI quantitative parameters with biological markers extracted from stereotactic 
image-guided biopsies. Glioblastoma multiforme, the most frequent primary tumour of the 
central nervous system, remains one of the most lethal human cancers despite intensive 
research. Analysis of glioblastoma intra-tumour heterogeneity is an original approach since 
this aspect could provide a key to understanding the origin and recurrence of glioblastoma. 
The project aims to utilize existing methods such as Dynamic Contrast Enhancement MRI 
(DCE-MRI) or Texture Analysis, which are able to delimit the boundaries of four different 
sectors (the necrosis, the tumour, the interface between tumour and parenchyma, isolated 
infiltrated cells in normal parenchyma) (see Fig. 1). These methods were used in a specific 
and comparative study of glioblastoma cells belonging to these four sectors in the same 
patients, using global as well as more specialized approaches (for instance, apoptosis and 
glioma metabolism) based on the competences of the research consortium involved. The 
imaging, mechanistic, genomics and proteomics data were correlated to assess their respective 
contributions to understanding the growth and recurrence of the tumour. The project was 
organized into four inter-related Work Packages (WP): WP1: Tumour heterogeneity and 
margin by quantitative MRI, WP2: Isolation of the different cell populations by primocultures 
from peroperative computer-guided biopsies, WP3: Genomic and proteomic comparative 
studies of the four cell populations extracted from four sectors of the glioblastoma, WP4: 
Comparative biological studies of the cell populations. 
For The WP1 of the GOGP including a common MRI protocol implemented on six 
different MRI devices, a key point is the initial acceptance of imaging devices and sequences. 
For this purpose, and to allow comparison of quantitative patient data [14], we employed a 
specific common protocol for device acceptance based on MRI quality assessment. We 
included 6 different MRI devices located at 6 hospital units up to 300 km apart. The aim of 
this WP was to find new imaging parameters obtained with non-invasive methods to highlight 
the heterogeneity of the glioblastoma and enhance the prognostic grading. Several groups 
have attempted to characterize intracranial tumour tissue with various MRI-MRS parameters 
such as relaxation time [16, 17], Contrast-Enhanced Dynamic MR Imaging [18], diffusion 
MRI [19, 20] and in vivo MRS [21,22]. These previous approaches were usually seldom 
coordinated in multicentre studies to establish correlations between parameters extracted from 
imaging and data from mechanistic, genomic and proteomic analyses. In the present WP, the 
imaging biomarkers need to be correlated with biological biomarkers extracted from biopsies. 
Such a programme involves a common acquisition and image processing protocol, which 
makes it possible to compare images obtained at the different sites and extract quantitative 
parameters. Moreover, it remains to be established whether these parameters and image-
guided biopsy samples refer to the same spatial coordinates. Then, we require quality 
assessment of the MRI systems to check that the instruments have homogenous and stable 
characteristics, thus enabling inclusion of patient data in the multicentre project. 
 Materials and methods 
 
MR Imaging systems 
Our study included six different 1.5T MRI devices from three manufacturers (Siemens 
Medical Solutions, Erlangen, Germany; Philips Medical Systems, Best, Netherlands; General 
Electric, Milwaukee, USA). These MRI devices were located at six different centres, which 
needed to participate in data collection over a period of two years. Different radiofrequency 
head coils were used according to the site. In the following, we refer to the imagers using 
letters from A to G. Imagers A, E and G were made by the same manufacturer as C, D and F. 
During the GOGP test period, because of obsolescence, device E was replaced by device F on 
one site. To allow acceptance of MRI devices in the multicentre project, a QA was performed 
on each site. A second QA for verification was carried out on some sites. There were two 
controls on imagers A, B, D and G, and one control on imagers C, E and F.  
MR Imaging sequences 
The GOGP protocol includes routine imaging sequences as well as specific sequences. Using 
this protocol, we selected the sequences needed for the quantification of tumour 
heterogeneity: i) T1W (SE for GE, Philips and Siemens); ii) T2W (Fast Spin Echo for General 
Electric and Turbo Spin Echo for Philips and Siemens) contrast spin echo sequences acquired 
for texture analysis purposes [23], which can provide new information not detectable by the 
radiologist; iii) T1 contrast gradient echo (Spoiled Gradient echo for General Electric, Fast 
Field Echo-T1 for Philips and FLASH for Siemens) with a 90° flip angle (DYN90) as used 
for DCE-MRI. This technique allows the calculation and parametric mapping [22] of the 
fractional vascular, interstitial and cellular volumes of glioblastomas and iv) another set of T1 
contrast spin echo sequences with multiple repetition times (T1SE-Multi TR) was included in 
the QA to validate T1 measurements and physiological parameters extracted from DCE-MRI 
data. Other imaging parameters are listed in Table 1. All user accessible filters except for the 
uniformity one were disabled. For these acceptance tests, all acquisitions were performed in 
the axial-transverse direction, as this is the slice orientation mainly used for the GOGP 
protocol. For the image-guided biopsy, two different software applications were used: 
Brainlab (Feldkirchen, Germany) for sites A, E, F and G, and Medtronic Inc (Minneapolis, 
USA) for sites B, C and D. 
 
 
Test-Objects and  Image Analysis (see supplementary data 1 for a complete description) 
The SpinSafety® test-objects (Spin Safety Ltd, Rennes, France) is a commercially 
available version of the Eurospin test-objects previously described [1]. The same set of four 
test-objects was used at the six imaging centres. The GOGP imaging protocol for each patient 
included dynamic acquisition and T1 measurements using 6 reference tubes containing 
solutions with known T1s covering values encountered in the brain. Each site received a set of 
six such tubes. During the GOGP imaging protocol, these tubes were placed around each 
patient’s head (see Fig. 1a) and used as an external reference for T1 correction. During the 
QA protocol, these tubes were imaged along with the TO4 (see Fig. 1b). 
The measurement protocol was developed in accordance with the Eurospin Methods 
for determining the parameter values following the published recommendations [1, 2, 3, 7, 8, 
9]. The total acceptance protocol time for each imager was approximately 2h30 min. 
 
All images were examined by the same QA expert and reported on Excel spreadsheets. 
Student t-test for the conformity study and Analysis of Variance (ANOVA) were used to 
obtain statistical data. Reproducibility and repeatability were determined according to the ISO 
5725 standard. 
 
MRI devices acceptance guidelines. 
To our knowledge, no international guidelines have yet been proposed for the 
acceptance criteria of MRI devices in such a protocol. Such guidelines would be too 
dependent on the specific goal of the study. However, based on the few previous studies [12, 
25, 26, 27, 28, 29] and as a compromise between technical limitations and optimal 
requirements under clinical condition, we decided on the following acceptance guidelines for 
the GOGP based on the 10 selected parameters. We wished to attain an accuracy of around 1 
mm for the geometrical parameters to enable a good positioning during neuronavigation. 
Therefore, the acceptable errors on the geometrical parameters must be in agreement with the 
values listed on Table 2. These geometrical data are globally better than the mean clinical 
positioning  errors quoted in the literature [25], which range from 1 mm with implantable 
fiducial markers and point-pair matching to 5 mm with surface matching, while both are 
measured when redundant fiducial markers are used [25]. To allow a good quantification of 
the tumour heterogeneity using the DCE-MRI and texture analysis, the signal variations must 
be as small as possible: 5% of variation seems to be a good compromise. The SNR is a key 
parameter for the subsequent T1 measurement procedure, which is needed to compute the 
dynamic contrast enhancement parameters used by the GOGP. Hence, we developed a Monte 
Carlo simulation under Mathematica® (version 5.1; Wolfram Research, IL, USA) to 
propagate the noise [30] measured on images to the errors on computed TI values. The Monte 
Carlo simulations of the spoiled gradient echo sequence were ran 10 000 times with the 
addition of random Gaussian noise. The T1 values were computed from the signal equation 
[31], and the standard deviation on T1 expressed in seconds over the 10 000 runs. Standard 
deviation of T1 expressed in percentage is plotted against SNR in the range of 25 to 250 and 
for T1 values ranging from 0.1 to 2 s (see Fig. 5). Considering a maximum T1 of 2s, the 
simulation shows that a relative error less than 10% on T1 measurement is obtained with a 
minimum SNR of 75. Such a relative error is acceptable [14] for the subsequent dynamic 
quantification procedure. 
 
 
Results 
Table 3 summarizes the main results for the three representative sequences (T2W, T1W and 
DYN90) of the protocol, reporting the means and standard deviations of the parameter values. 
 
Geometry-related parameters 
Spatial resolution (SR) was analysed with an ANOVA test using the sequence as a between-
subjects factor (i.e., T2W, T1W and DYN90). We observe no consistent main effect 
according to the sequences, with means of 0.93, 0.96, and 1.06 for the T2W, T1W and 
DYN90, respectively. The Student t-test also indicates that spatial resolution measurements 
are close to the theoretical value of 0.94 mm. Furthermore, as can be seen on Table 4, the 
results on each device do not exceed our acceptable errors. 
Slice thickness (ST) was analysed with an ANOVA test using the sequence as a 
between-subjects factor (i.e., T2W, T1W and DYN90). We observe a consistent main effect 
according to the sequences, with means of 5.2 mm, 5.0 mm and 5.8 mm for the T2W, T1W 
and DYN90, respectively, F(2, 30) = 12.9, p < 0.0001. The Student t-test also indicates that 
slice thickness measurements, except for sequence DYN90, are close to the theoretical value 
of 5 mm, with p≤0.001. We note that, for this last sequence, the slice thickness is often greater 
that the acceptable error of our clinical study (Table S2, supplementary data 2). 
The others parameters (slice position SP, mean diameter GD1, diameter distortion rate 
GD2, square side GD3 and diagonal distortion rate GD4) are constant over the sequences and 
close to the theoretical values. For example, as presented in Table supplementary data2 S3, 
mean diameters measured during the quality assessment show a maximum distortion of 2 mm. 
This is slightly more (0.1mm) than our acceptable error. The Student t-test also indicates that 
mean diameter measurements are close to the theoretical value of 190 mm. 
 
MR signal-related parameters 
Figure 3 presents the detailed results of measurements on each MRI system (A to G) using the 
three sequences, yielding SNR values ranging from 76 to 296. The mean SNR ranges from 
203 in the case of T2W to 154 in the case of DYN90. The signal variations on frequency 
(SVF) and readout (SVR) directions (see Table 2) are less than 5%.  
 
Calculated T1 
In this study, we analysed the T1 measurements of TO4 and the external reference tubes. As 
with the other tests, the same TO4 was used at each site. Table 5 reports the mean T1, T1 
repeatability and reproducibility variation coefficients for each tube. These statistical data 
show that the repeatability variation coefficient ranges from 8.9% to 11.4%, and the 
reproducibility variation coefficient from 7.4% to 13.3%.  
The reproducibility of the external reference tubes was also checked. As an example, 
Fig. 4 gives the results of measurements for one of these tubes taken one year apart at the 6 
centres. On this graph, we show the two T1 measurements and the mean T1 for each site. We 
can see that the general mean for this external reference tube is 416 ms and the reproducibility 
standard deviation is 24 ms. 
 
Discussion 
In the context of a multicentre clinical study (the GOGP), we have developed a 
protocol to check 10 parameters from signal and geometry-related parameters and T1 
assessment. This protocol was disseminated over 6 sites equipped with 1.5T machines from 
three different manufacturers. 
The precise positioning of the phantom in the transverse plane is not an issue since a 
marker is printed on each object so it can be precisely aligned with the laser of the MRI unit. 
In this study, we restrict ourselves to transverse acquisitions, while, in common clinical 
protocols, the imaging of sagittal or coronal incidence is mainly used, which can also be 
checked through a QA procedure. However, this latter approach would require a time 
consuming procedure lasting more than three hours, which is difficult to carry out on clinical 
sites. Moreover, our goal is not to develop a QA procedure to test the machine but rather to 
enable the inclusion of patient data in a specific clinical protocol. We chose transverse 
incidence because most of the acquisitions of the GOGP are of this type. The choice of pulse 
sequence to be used in QA is also dictated by the clinical protocol, which depends mainly on 
spin echo T1, turbo spin T2 and dynamic T1 Gradient echo acquisitions. 
The results of the QA for geometrical parameters are accurate to around 2 mm, which 
allows a acceptable positioning of the biopsy region by neuronavigation imaging. Distortion 
results are comparable, being relatively small and independent of the pulse sequences, as 
shown by the standard deviation values. When comparing the slice thickness results between 
sequences, DYN90 yields the worst results. Nevertheless, the significantly increased slice 
thickness compensates for the inherently lower SNR of this short imaging time sequence (less 
than 30 s), at the expense of the partial volume effect. 
The SNR obtained for the DYN90 is again lower than the SNR for the T1W and T2W 
sequences. During the QA procedure, we obtained a mean measured SNR of 154 for the 
DYN90 sequence, which corresponds to a maximum error on T1 of 0.02 s and 0.08 s, for T1 
values of 1 s and 2s, respectively (See Figure 5). This represents a relative error on the 
computed T1 of less than 4%, which is acceptable [14] for the subsequent dynamic 
quantification procedure. It should also be noted that, because we make use of a ratiometric 
method [31], the frequency and phase signal variations do not influence these T1 
computations. 
Moreover, T1 measurements have a good precision in terms of reproducibility and 
repeatability. This level of precision is mandatory in the T1 measurement procedure of the 
WP1, since it enables a comparison of the dynamic contrast enhancement parameters obtained 
at the six centres.  
Our choice of sequences for the QA was guided by two principles: first, to have simple 
sequences that were sufficiently standardized to be implemented without too much difficulty 
on each device, even from different manufacturers, and, second, to stay as close as possible to 
the real sequences used in the clinical research protocol we wanted to assess. 
The time required for these tests (2h30 for a single control procedure) is not easily 
available on clinical machines for monthly follow-up throughout the protocol duration (two 
years for GOGP). One solution could be to shorten the procedure by removing the T1 
measurements, which take about 1 hour, and also reduce the number of tested sequences. 
Performing this “light” procedure lasting about 15 minutes could be used on each system to 
check the main geometrical parameters and signal-to-noise ratio on a monthly basis during the 
duration of the project. Another time-consuming task is processing all the data gathered 
during each QA procedure, which takes about 16 hours. In our study, processing was 
performed manually, which could lead to possible errors. An automatic analysis and report 
procedure could avoid this source of errors as well as reduce the amount of time needed for 
the analysis. 
 
Conclusions 
In conclusion, quality assessment testing is mandatory in any clinical research project 
involving quantitative MRI. In the GOGP protocol, we used six machines from different 
manufacturers set up on different sites. We propose a method for quality assessment based on 
the main pulse sequences of the GOGP clinical protocol using four test-objects to assess 
geometry, SNR, uniformity parameters and T1 measurements. As a result of these different 
QA tests, we were able to include patients from the different sites and extract tumour 
quantification parameters that are comparable irrespective of the origin of the images. In 
addition, we could make sure that the extracted MR parameters and image-guided biopsy 
samples referred to the same spatial coordinates. It should be mandatory to generalize the 
application of this kind of QA procedure from the outset of a multicentre clinical project. 
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Fig. 1 Fig 1. (A) Postcontrast brain MR image from T1 dynamic series in axial
plane. The four regions of the glioblastoma are labeled: (1) necrosis, 
(2) tumor, (3) interface between tumor and parenchyma, (4) isolated infiltrate
cells in a normal parenchyma. (B) TO4 and a set of six tubes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Relative T1 error plotted against SNR and T1 values for the 
Dyn90 sequence. 
Fig. 3 SNR in different MRI Devices for T2W, 
T1W and DYN90 sequences 
Fig.4 Statistical data for an external reference tube
Table 1.  Imaging acquisition parameters. Slice thickness is 5 mm in all sequences 
TR: Repetition Time. TE: Echo Time. FOV: Field Of View. 
 
 
 
 
 
Table 2. Acceptable errors for T2W, T1W and DYN90 sequences 
Parameters Acceptable 
Errors 
  
SNR ≥75 
Frequency signal variations 
(%) 
5% 
Phase signal variations (%) 5% 
Spatial resolution (0.94 mm) 50% 
Slice thickness (5 mm) 20% 
Mean diameter (190 mm) 1% 
Diameter distortion (%) 1% 
Square side distortion (%) 1% 
Diagonal Distortion (%) 1% 
Slice Position (gap in mm) 1, 
0.5* 
20% 
 
 
 
 
 
 
 
 
 
Sequenc
es TR (ms) 
TE 
(ms) 
FOV 
(mm) Matrix 
Averag
es 
Nb 
slices 
Gap 
(mm
) 
Echo 
train 
DYN90 150 5.6 180x240 192x256 1 13 0.5 - 
T2W 3000 80 240x240 256x256 2 24 1 18 
T1W 440 10 240x240 256x256 2 24 1 - 
T1SE-
Multi 
TR 
50-100-
200-
350-
750-
1000-
1500-
3000-
6000 
10 240x240 256x256 1 1 - - 
 
 
 
 
 
Table 3. Mean parameter values, standard deviations for T2W, T1W and DYN90 sequences 
Parameters T2W T1W DYN90 
Mea
n 
Std Mea
n 
Std Mea
n 
Std 
SNR 203 45 184 37 154 59 
Frequency signal variations 
(%) 
3.8 2.6 4.5 2.6 3.9 2.7 
Phase signal variations (%) 3.7 2.7 3.6 2.7 2.7 2.7 
Spatial resolution (0.94 mm) 0.93 0.15 0.96 0.15 1.06 0.21 
Slice thickness (5 mm) 5.2 0.3 5.0 0.1 5.8 0.5 
Mean diameter (190 mm) 189.
7 
0.6 189.
7 
0.6 189.
8 
0.8 
Diameter distortion (%) 0.6 0.2 0.5 0.2 0.6 0.2 
Square side distortion (%) 0.3 0.3 0.2 0.3 0.3 0.3 
Diagonal Distortion (%) 0.3 0.3 0.3 0.3 0.2 0.2 
Slice Position (gap in mm) 1, 
0.5* 
0.92 0.15 0.93 0.15 0.51
* 
0.15 
 
 
Table 4. Spatial Resolution in mm for the 3 sequences of each MRI device. 
 Spatial Resolution – 
theoretical value= 0.94 mm 
MRI 
Device 
T2W T1W DYN90 
A 0.83 0.86 0.94 
B 0.85 0.87 0.92 
C 0.94 0.91 0.93 
D 0.96 0.94 0.94 
E 0.75 0.83 1.04 
F 0.90 0.98 1.16 
 
 
 
Table 5. T1 Mean Values, Repeatability, and Reproducibility Variation 
Coefficients for Each Tube of TO4 
Supplementary data 1 
Test-Objects 
The  SpinSafety®  test‐objects  (Spin  Safety  Ltd, Rennes,  France)  is a commercially available 
version of the Eurospin test‐objects previously described [1]. The same set of four test‐objects was 
used at the six imaging centres. They were filled with a dilute solution of copper sulphate to obtain a 
T1 of 350 ms at 1.5T and 25°C. Figure S1 presents the transverse MRI slice images of the test‐objects. 
Parameters measured with SpinSafety Test‐Object 1 (TO1) and TO4 were considered to control the 
quality of GOGP  sequences used  for  T1 measurements  and quantification, whereas  TO2  and  TO3 
were considered to control the quality of spatial localization and geometry distortions of sequences 
used for neuronavigation and MRI‐guided biopsies [23]. TO1 is a homogeneous cylinder designed to 
be used for the measurement of signal‐related parameters. TO2 is dedicated to the measurement of 
geometrical parameters; it contains two angled plates and two wedges for measuring slice thickness, 
two Polymethyl Methacrylate blocks for measuring spatial resolution and four plates in square form 
used for measuring square and diagonal distortions. TO3 contains two rods used for estimating slice 
position. TO4 contains 12 tubes filled with solutions having different T1 and T2 relaxation times (see 
Table  S1).  The  GOGP  imaging  protocol  for  each  patient  included  dynamic  acquisition  and  T1 
measurements  using  6  reference  tubes  containing  solutions  with  known  T1s  covering  values 
encountered  in  the  brain.  Each  site  received  a  set  of  six  such  tubes.  During  the  GOGP  imaging 
protocol,  these  tubes were placed around each patient’s head  (see Fig. 1) and used as an external 
reference  for T1 correction. During  the QA protocol,  these  tubes were  imaged along with  the TO4 
(see Fig. S1d). 
The measurement  protocol was  developed  in  accordance with  the  Eurospin Methods  for 
determining the parameter values following the published recommendations [1, 2, 7, 8, 9]. The four 
TOs were positioned in a transverse plane at the centre of the head coil. The ten parameters under 
examination were: signal variations along frequency encoding direction, signal variations along phase 
encoding  direction,  Signal‐to‐Noise  Ratio  (SNR),  slice  thickness,  slice  position,  spatial  resolution, 
mean diameter, circle diameter distortion, square side and diagonal distortions and T1 accuracy (see 
Table 3). For the three sequences of the protocol (T1W, T2W and DYN90), all these parameters were 
determined in a transverse plane, using the appropriate TO. Measurement of T1 of the TO4 and the 
set of six reference tubes was performed with the T1SE‐Multi TR. The total acceptance protocol time 
for each imager was approximately 2h30 min. 
Image analysis 
Images  in DICOM [24] format were transferred by each site onto a central Work Station for 
processing. Signal variations along the frequency and phase encoding directions were calculated by 
tracing profiles on TO1  images [2]. SNR was obtained by multiplying the mean signal by the square 
root  of  2  and  dividing  by  the  standard  deviation  of  the  subtracted  image  resulting  from  two 
successive TO scans [7]. Geometrical distortion in the image plane was determined by measuring the 
mean diameter, the diameter distortion rate, the square distortion rate and the diagonal distortion 
rate on  the  TO2.  To determine  the  slice  thickness,  an  intensity profile was measured  through  an 
angle  plate  of  the  TO3  to  calculate  the  peak  width  [9].  2D  spatial  resolution  was  obtained  by 
measuring an intensity profile through a block in TO2. The resolution could then be calculated from 
the Modulation Transfer Function (MTF) [3]. The relative distance of the angle rods of the TO3 was 
used to obtain slice position. For T1 measurements, signals of the different tubes of TO4 at different 
repetition times (TR) were fitted to the signal equation of the saturation recovery method using the 
Solver  Program  of  Microsoft  Excel  (version  2003,  Microsoft  Corporation,  Seattle,  USA).  For  one 
manufacturer,  specific  tools were developed  to  restore  the  initial  image  intensities needed  for T1 
measurements. The  ImageJ  software  (W. Rasband, National  Institutes of health, USA) was used  to 
analyse  all  the  images. All  images were  examined  by  the  same QA  expert  and  reported  on  Excel 
spreadsheets. Student t‐test for the conformity study and Analysis of Variance (ANOVA) were used to 
obtain statistical data. Reproducibility and repeatability were determined according to the ISO 5725 
standard. 
 
Table S1. T1 and T2 values references for the tubes of the TO4. 
Tubes  T1 (ms)  T2 (ms) 
1  119  9 
2  118  10 
3  112  9 
4  117  9 
5  166  13 
6  353  56 
7  450  64 
8  779  83 
9  706  77 
10  787  98 
11  1036  124 
12  758  84 
 
 
 
Fig. S1 Transversal MRI slice images of the Test Objects (a) TO1, (b) TO2, 
(c) TO3, (d) TO4 and a set of six tubes 
(b)
(c)  (d)
(a) 
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Table S1.  Imaging assessment parameters 
 
 
Table S2: Slice thickness in mm for the 3 sequences of each MRI device. 
  Slice thickness – theoretical 
value= 5.00 mm 
MRI Device  T2W  T1W  DYN90 
A  5  4.8  6.4 
B  5.2  4.8  5.7 
C  5  5  5.5 
D  5.9  5.1  6.3 
E  5.9  4.9  6.5 
F  5.1  4.9  6.5 
 
Parameter Test Object 
Frequency signal 
variations 
TO1 
Phase signal variations TO1 
SNR TO1 
Mean diameter TO2 
Diameter distortion  TO2 
Square side distortion TO2 
Diagonal distortion TO2 
Slice thickness TO2 
Spatial resolution TO2 
Slice position TO3 
T1 accuracy TO4 
Table 8: Mean Diameter in mm for the 3 sequences of each MRI device. 
  Mean Diameter – theoretical 
value= 190 mm 
MRI Device  T2W  T1W  DYN90 
A  189.1  189.6  189.6 
B  190.3  190.1  190.2 
C  189.8  189.9  190 
D  190.3  189.8  190.1 
E  189.7  189.5  189.8 
F  189.0  188.9  188.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
